Q-omics provides the consensus-scored RPL21P16 profile across patient tissues and cancer cell-line models. RPL21P16 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL21P16 is differentially expressed in 6, with the highest sampling consensus in UCEC. Additionally, RPL21P16 RNA expression shows 15,970 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, UCEC, and THYM as cancer lineages where RPL21P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL21P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL21P16 survival associations across molecular data types. RPL21P16 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL21P16 RNA expression–survival associations across cancer types. High RPL21P16 expression shows unfavorable associations in ACC, OV and LIHC, but favorable associations in MESO, LGG and THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL21P16 RNA expression.
This table summarizes RPL21P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL21P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL21P16 shows lower tumor expression in UCEC, LUAD, KICH and BRCA and higher tumor expression in KIRC and CHOL. The UCEC box plot shows higher RPL21P16 RNA expression in normal versus tumor tissue (log2 FC = −1.008, t-test p = .001).
This table shows molecular features associated with RPL21P16 in patient tissues and cancer cell lines. In patient samples, RPL21P16 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
